Company Overview

Update
Founded:
2002
Founders:
Mark Pruzanski
Headquarters:
New York, NY
IPO:
Went Public on Oct 11, 2012
Stock:
ICPT
Categories:
Health Care, Biotechnology
Description:
Intercept Pharmaceuticals develops small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases.

Detailed Description

Update

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, a FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases. Intercept Pharmaceuticals, Inc. was founded in 2002 and is based in New York, New York.

Current Team (5)

Update

Funding Rounds (2) - $55M

Update

Board Members and Advisors (8)

Update

Investors (1)

Update
  • B1ce9d2887c930e2d5d82b64a7eebcb9

    OrbiMed Advisors

    OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under...

Offices/Locations (1)

Update
  • Headquarters

    18 Desbrosses Street

    New York, NY 10013

    USA

Images (1)

Update
  • F59dddf08a32296d5f776c883326ab99